Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06160167 · ClinicalTrials.gov registry record
Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 4,204
- Enrollment target
NCT06160167 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 4,204 participants.
The verdict
NCT06160167 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 4,204 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical records in the Flatiron Health database.
Interventions
- DRUG IMiD treatment
- DRUG No IMiD treatment
- DRUG Systemic therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,204 participants |
| Start Date | 2023-10-01 |
| Est. Completion | 2024-08-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06160167
The ClinicalTrials.gov registry entry for NCT06160167 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 4,204 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which IMiD treatment is the first listed.
NCT06160167 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06160167 about?
NCT06160167 is a clinical study titled "Incidence of Hyperpigmentation in Black Patients With Multiple Myeloma Treated With Immunomodulatory Drugs". The purpose of this study is to measure the incidence of hyperpigmentation in Black participants with multiple myeloma (MM) treated with immunomodulatory drugs (IMiDs) compared with Black participants with MM not treated with IMiDs. The study will use de-identified data from electronic medical recor...
What is the current status of trial NCT06160167?
This trial is currently completed. The enrollment target is 4,204 participants. The study started on 2023-10-01. Estimated completion is 2024-08-01.
What interventions are being tested in trial NCT06160167?
The interventions under investigation include: IMiD treatment (DRUG), No IMiD treatment (DRUG), Systemic therapy (DRUG).
Who is sponsoring clinical trial NCT06160167?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.